Drugs · Entity Annotation Prototype (beta)

1articles mentioning drugs

10drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Mec-V ×

Mec-V

This drug is selected. Its supporting articles are shown below.

Mec-V1

Articles mentioning Mec-V

1 articles · page 1 of 1

523 Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC

jitc · abstract · 2025-11-04 · 10 matching annotations

93.6%

mecbotamab vedotin eribulin Mec-V trabectedin pazopanib BA3011 leiomyosarcoma

…cancer (NSCLC) patients with mutated KRAS in a phase 2 trial of mecbotamab vedotin (CAB-AXL-ADC). Presented at: European Lung Cancer Congress; 202…

Browse drugs

Mec-V

Articles mentioning Mec-V

523 Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC